BPMC - Blueprint Medicines Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
81.20
+2.23 (+2.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close78.97
Open78.43
Bid0.00 x 900
Ask0.00 x 800
Day's Range78.33 - 81.69
52 Week Range44.58 - 89.00
Volume320,522
Avg. Volume504,511
Market Cap3.967B
Beta (3Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-6.08
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est105.38
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents6 hours ago

    Edited Transcript of BPMC earnings conference call or presentation 9-May-19 12:30pm GMT

    Q1 2019 Blueprint Medicines Corp Earnings Call

  • Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations
    PR Newswire7 days ago

    Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations

    -- Blueprint Medicines to Host Investor Event and Webcast at ASCO on Monday, June 3, 2019 -- CAMBRIDGE, Mass. , May 16, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision ...

  • 3 Stocks With Big News Coming at ASCO 2019
    Motley Fool8 days ago

    3 Stocks With Big News Coming at ASCO 2019

    These cancer drug developers could report market-moving news soon.

  • How Much is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Getting Paid?
    Simply Wall St.9 days ago

    How Much is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Getting Paid?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
    Zacks10 days ago

    Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates

    Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.

  • Blueprint Medicines (BPMC) Q1 2019 Earnings Call Transcript
    Motley Fool13 days ago

    Blueprint Medicines (BPMC) Q1 2019 Earnings Call Transcript

    BPMC earnings call for the period ending March 31, 2019.

  • Blueprint Medicines (BPMC) Reports Q1 Loss, Misses Revenue Estimates
    Zacks14 days ago

    Blueprint Medicines (BPMC) Reports Q1 Loss, Misses Revenue Estimates

    Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -8.20% and -75.67%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press14 days ago

    Blueprint Medicines: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.98. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • Blueprint Medicines Reports First Quarter 2019 Financial Results
    PR Newswire14 days ago

    Blueprint Medicines Reports First Quarter 2019 Financial Results

    -- Avapritinib NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST on track for submission to FDA in second quarter -- -- BLU-667 granted Breakthrough Therapy Designation for the treatment of RET fusion-positive ...

  • Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
    Zacks15 days ago

    Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

    Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

  • Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference
    PR Newswire15 days ago

    Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference

    CAMBRIDGE, Mass. , May 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  ...

  • Markit16 days ago

    See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

    Blueprint Medicines Corp NASDAQ/NGS:BPMCView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.95 billion over the last one-month into ETFs that hold BPMC are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
    PR Newswire21 days ago

    Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

    CAMBRIDGE, Mass. , May 2, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, ...

  • Did Hedge Funds Drop The Ball On Blueprint Medicines Corporation (BPMC) ?
    Insider Monkey24 days ago

    Did Hedge Funds Drop The Ball On Blueprint Medicines Corporation (BPMC) ?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • Earnings Preview: Blueprint Medicines (BPMC) Q1 Earnings Expected to Decline
    Zacks29 days ago

    Earnings Preview: Blueprint Medicines (BPMC) Q1 Earnings Expected to Decline

    Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 3 Small-Cap Biotech Stocks to Watch Now
    Motley Fool2 months ago

    3 Small-Cap Biotech Stocks to Watch Now

    These under-the-radar stocks could be poised to make big moves in the coming months.

  • Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
    PR Newswire2 months ago

    Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock

    CAMBRIDGE, Mass., April 2, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the closing of its previously announced underwritten public offering of 4,662,162 shares of its common stock at a public offering price of $74.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock. Blueprint Medicines estimates net proceeds from the offering will be approximately $327.2 million, after deducting underwriting discounts and commissions and estimated offering expenses. Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Guggenheim Securities, LLC and Wedbush Securities Inc. acted as co-lead managers for the offering. A registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with the Securities and Exchange Commission (SEC) and has become effective.

  • Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session
    Zacks2 months ago

    Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session

    Blueprint Medicines (BPMC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

  • If You Had Bought Blueprint Medicines (NASDAQ:BPMC) Stock Three Years Ago, You Could Pocket A 337% Gain Today
    Simply Wall St.2 months ago

    If You Had Bought Blueprint Medicines (NASDAQ:BPMC) Stock Three Years Ago, You Could Pocket A 337% Gain Today

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Investing can be hard but the potential fo an individual stock to pay off big time inspires us. You won't get it ri...

  • Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
    PR Newswire2 months ago

    Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

    CAMBRIDGE, Mass., March 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the pricing of an underwritten public offering of 4,054,054 shares of its common stock at a public offering price of $74.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines has granted the underwriters a 30-day option to purchase up to an additional 608,108 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock were offered by Blueprint Medicines.

  • Blueprint Medicines Expediates Filings for Key Candidates
    Zacks2 months ago

    Blueprint Medicines Expediates Filings for Key Candidates

    Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.

  • Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
    PR Newswire2 months ago

    Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

    CAMBRIDGE, Mass., March 27, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has commenced an underwritten public offering of $300,000,000 in shares of its common stock. In addition, Blueprint Medicines expects to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 in shares of its common stock in connection with the public offering. All shares of common stock will be offered by Blueprint Medicines.

  • Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress
    PR Newswire2 months ago

    Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress

    -- Avapritinib: plan to submit MAA for PDGFRα D842V mutant GIST and fourth-line GIST in Q3 2019 and NDA for advanced systemic mastocytosis in Q1 2020 -- -- BLU-667: plan to submit NDA for previously treated ...

  • 5 Cancer-Fighting Stocks to Boost Portfolio Gains
    Zacks2 months ago

    5 Cancer-Fighting Stocks to Boost Portfolio Gains

    It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.